top of page
Hematuria Cancer Risk Score in Combination With Oncuria-Detect for Patients Undergoing Evaluation for Hematuria
Date: August 20, 2025 PMID: PMC12578602 Category: N/A Authors: John R Heard, Ian Pagano, Charles Rosser, Wei Shen Tan Abstract: 40846188/ DOI: 10.1016/j.urology.2025.08.031 Objective: To evaluate the performance the Hematuria Cancer Risk Score (HCRS) in combination with the urine-based biomarker test Oncuria-Detect for the detection of bladder cancer in a cohort of patients referred for hematuria evaluation. Methods: A cohort of 365 patients undergoing microscopic and gross h
bgtaylor1
Nov 11, 20252 min read
BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations
Date: August 19, 2025 PMID: 10.1007/s43441-025-00860-5 Category: N/A Authors: Xiaohan Chi, Ying Yuan, Ruitao Lin Abstract: 40830695 Background: Personalized cancer treatment using combination therapies offers substantial therapeutic benefits over single-agent treatments in most cancers. However, unmet clinical needs and increasing market competition pressure drug developers to quickly optimize combination doses and clearly demonstrate the contribution of each component when d
bgtaylor1
Nov 11, 20252 min read
PoweREST: Statistical power estimation for spatial transcriptomics experiments to detect differentially expressed genes between two conditions
Date: July 29. 2025 PMID: PMC12316394 Category: N/A Authors: Lan Shui, Anirban Maitra, Ying Yuan, Ken Lau, Harsimran Kaur, Liang Li, Ziyi Li; Translational and Basic Science Research in Early Lesions Research Consortia Abstract: 40729405 Recent advancements in spatial transcriptomics (ST) have significantly enhanced biological research in various domains. However, the high cost for current ST data generation techniques restricts the large-scale application of ST. Consequently
bgtaylor1
Nov 11, 20252 min read
bottom of page